Co-Authors
This is a "connection" page, showing publications co-authored by AMIR A JAZAERI and PAMELA THERESE SOLIMAN.
Connection Strength
1.366
-
Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum-resistant ovarian cancer. Cancer. 2024 04 01; 130(7):1061-1071.
Score: 0.243
-
Hormone receptor status and the role of oophorectomy in uterine leiomyosarcoma. Gynecol Oncol. 2022 Oct 18.
Score: 0.225
-
Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancer. Gynecol Oncol. 2021 07; 162(1):24-31.
Score: 0.204
-
Gene Expression Analysis Identifies Novel Targets for Cervical Cancer Therapy. Front Immunol. 2018; 9:2102.
Score: 0.170
-
A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice. Gynecol Oncol. 2018 11; 151(2):374-380.
Score: 0.169
-
Potential immunotherapy targets in recurrent cervical cancer. Gynecol Oncol. 2017 06; 145(3):462-468.
Score: 0.152
-
Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer. Clin Cancer Res. 2021 12 01; 27(23):6354-6365.
Score: 0.052
-
Factors associated with response to neoadjuvant chemotherapy in advanced stage ovarian cancer. Gynecol Oncol. 2021 07; 162(1):65-71.
Score: 0.051
-
Pembrolizumab in vaginal and vulvar squamous cell carcinoma: a case series from a phase II basket trial. Sci Rep. 2021 02 11; 11(1):3667.
Score: 0.050
-
Correlation of surgeon radiology assessment with laparoscopic disease site scoring in patients with advanced ovarian cancer. Int J Gynecol Cancer. 2021 01; 31(1):92-97.
Score: 0.049